Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772787 | 0.82 | NPSR1 (0.55) | NPSR1VCPHSP90AA1MEN1KMT2A | |
| SCHEMBL5769172 | 0.81 | NPSR1 (0.64) | NPSR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11636289 | 0.80 | NPSR1 (1.00) | NPSR1VCPFFAR1PAMDRD2 | |
| SCHEMBL10255248 | 0.75 | NPSR1 (0.65) | NPSR1VCPFFAR1PAMDRD2 | |
| SCHEMBL25918159 | 0.75 | NPSR1 (0.70) | NPSR1VCPDRD2HTR2AHTR2C | |
| SCHEMBL972786 | 0.74 | NPSR1 (0.47) | NPSR1VCPFFAR1DRD2HTR2A | |
| SCHEMBL6562126 | 0.73 | NPSR1 (0.49) | NPSR1VCPFFAR1PAMFFAR4 | |
| SCHEMBL19823670 | 0.71 | NPSR1 (0.65) | NPSR1VCPFFAR1DRD2HTR2A | |
| SCHEMBL4189140 | 0.71 | NPSR1 (0.50) | NPSR1VCPFFAR1FFAR4UTS2R | |
| SCHEMBL6071442 | 0.70 | NPSR1 (0.58) | NPSR1FFAR1NPC1RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| EP-1326829-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002026706-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | NPSR1 2254/4885VCP 3952/4885FFAR1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.